Belite Bio, Inc (BLTE)

CIK 0001889109 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —
FY-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
—
Statements
Consolidated Balance Sheets
—
Consolidated Balance Sheets (P)
—
Consolidated Statements of Operations and Comprehensive Loss
—
Consolidated Statements of Operations and Comprehensive Loss (P)
—
Consolidated Statements of Convertible Preferred Shares and Shareholders' (deficit)
—
Consolidated Statements of Shareholders' Equity
—
Consolidated Statements of Cash Flows
—
Consolidated Statements of Cash Flows (P)
—
Notes
Accrued Expenses and Other Current Liabilities
—
Australia Research and Development Tax Incentive
—
Available-for-sale Investments
—
Cash and Cash Equivalents
—
Commitments and Contingencies
—
Convertible Preferred Shares
—
Cybersecurity Risk Management and Strategy Disclosure
—
Equity
—
Held-to-maturity Debt Securities
—
Held-to-maturity Investments
—
Income Tax
—
Insider Trading Arrangements
—
Insider Trading Policies and Procedures
—
Leases
—
Net Loss Per Share
—
Organization and Basis of Presentation
—
Other Receivables, Prepayments and Other Current Assets, Prepayments and Other Non
—
Pay Vs Performance Disclosure
—
Property and Equipment, Net
—
Related Party Transactions
—
Segment
—
Share-based Compensation
—
Subsequent Events
—
Summary of Significant Accounting Policies
—